Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
5
×
ipo
5
×
life sciences
national blog main
cancer
national top stories
san francisco blog main
san francisco top stories
cancer drugs
clinical trials
new york blog main
new york top stories
san francisco
sanofi
third rock ventures
warp drive bio
deals
drug discovery
fda
investing
revolution medicines
san diego blog main
san diego top stories
startups
the column group
vc
venture capital
accent therapeutics
acetylon pharmaceuticals
aducanumab
agios pharmaceuticals
alzheimer's disease
amblyotech
ambys medicines
amgen
asklepios biopharmaceutical
bioeurope
biogen
What
medicines
5
×
ipo
cancer
new
proteins
research
revolution
today
activity
aiming
ambys
approvals
big
bio
biogen
biotech
cancer’s
clamped
company’s
control
course
covid
deadly
deal
debuted
delays
despite
developing
development
discover
disease
diseases
drug
economic
experimental
family
fast
fda
formed
frontiers
Language
unset
Current search:
medicines
×
ipo
×
biotech
×
" boston top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?